<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902024000401203</article-id>
<article-id pub-id-type="doi">10.29193/rmu.40.4.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Comparación del desempeño de la tipificación de HPV y el test de Papanicolaou como métodos de triaje en la detección del cáncer de cuello uterino y sus lesiones precursoras en el Proyecto ESTAMPA-Uruguay]]></article-title>
<article-title xml:lang="en"><![CDATA[Comparison of HPV typing performance and the Pap test as triage methods in the detection of cervical cancer and its precursor lesions in the ESTAMPA-Uruguay Project]]></article-title>
<article-title xml:lang="pt"><![CDATA[Comparação do desempenho da tipificação de HPV e do teste de Papanicolau como métodos de triagem na detecção do câncer do colo do útero e suas lesões precursoras no Projeto ESTAMPA-Uruguay]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Beracochea]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caserta]]></surname>
<given-names><![CDATA[Benedicta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vero]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Podestá]]></surname>
<given-names><![CDATA[Marcos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ardao]]></surname>
<given-names><![CDATA[Gonzalo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rol]]></surname>
<given-names><![CDATA[Mary Luz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almonte]]></surname>
<given-names><![CDATA[Maribel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A11"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrero]]></surname>
<given-names><![CDATA[Rolando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A12"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalario Pereira Rossell Laboratorio de Biología Molecular Departamento de Patología Clínica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de la República, Área de Prevención del Cáncer de Cuello Uterino, Comisión Honoraria de Lucha contra el Cáncer Departamento de Métodos Cuantitativos Facultad de Medicina, Universidad de la República, Área de Prevención del Cáncer de Cuello Uterino, Comisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Comisión Honoraria de Lucha contra el Cáncer Área de Prevención del Cáncer de Cuello Uterino ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Policial  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de la República Cátedra de Anatomía Patológica Facultad de Medicina]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad de la República Clínica Ginecotocológica C Facultad de Medicina]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Laboratorio RIEPS  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Centro Hospitalario Pereira Rossell, Administración de Servicios de Salud del Estado (ASSE) Laboratorio de Biología Molecular Departamento de Patología Clínica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Servicios de Salud de las Fuerzas Armadas (SSFFAA) Banco de Tumores ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Organización Mundial de la Salud Early Detection Prevention and Implementation Branch Agencia Internacional de Investigación sobre Cáncer]]></institution>
<addr-line><![CDATA[Lyon ]]></addr-line>
<country>Francia</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Organización Mundial de la Salud Cervical Cancer Screening and Treatment and Implementation Research Departamento de Enfermedades No Transmisibles]]></institution>
<addr-line><![CDATA[Génova ]]></addr-line>
<country>Suiza</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Fundación Inciensa Agencia Costarricense de Investigaciones Biomédicas ]]></institution>
<addr-line><![CDATA[Guanacaste ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>40</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902024000401203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902024000401203&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902024000401203&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El Virus del Papiloma Humano (VPH), de alta prevalencia, causa cáncer cervicouterino en un bajo porcentaje de las infecciones. La detección de VPH debe completarse con un test de triaje que identifique mujeres que estén en mayor riesgo de desarrollar cáncer.  Objetivo: Analizar las mejores estrategias de triaje para la detección de lesiones precancerosas y cáncer cervicouterino.  Método: El estudio es retrospectivo, observacional. Se realizó test de Papanicolaou, test de VPH y tipificación a 1.984 mujeres en el período 2014-2019. Se analizó el desempeño de la tipificación parcial de VPH 16/18 combinado con citología (algoritmo A) y de la citología sin tipificación (algoritmo B) para el triaje de mujeres VPH positivas en tamizaje primario.  Resultados: 12,5% de las mujeres fueron VPH positivo. Se detectaron 27 casos NIC2+ (10,8% de las positivas). La sensibilidad para detectar NIC2+ en mujeres VPH-positivo fue mayor para el algoritmo A que el B (A=77,7%vs B=44,4%, p=0,006). La especificidad fue mayor para la citología sin tipificación (A=68,7% vs B=77,2%, p=0,002) pero con menor tasa de detección de NIC2+. El VPP fue similar (A=26,2% vs B=21,8%, p=0,30). El VPN fue mayor para la genotipificación con citología (A=95,5% vs B=90,6%, p=0,014). El riesgo absoluto para NIC2+ fue de 34,1% (CI95% 20,0-50,5) para los genotipos 16/18 y 8,7% (CI95% 4,4-15,0) para otros genotipos de alto riesgo.  Conclusiones: La tipificación parcial de VPH seguido de citología presenta una mayor sensibilidad para detectar lesiones NIC2+ y es mas eficiente en descartar enfermedad con respecto a la citología como método de triaje. Los genotipos de VPH 16/18 deben derivarse a colposcopía.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Human Papillomavirus (HPV), which has a high prevalence, causes cervical cancer in a low percentage of infections. HPV detection should be completed with a triage test that identifies women at higher risk of developing cancer.  Objective: To analyze the best triage strategies for detecting precancerous lesions and cervical cancer.  Method: The study is retrospective and observational. A Pap test, HPV test, and typing were performed on 1.984 women during the period 2014-2019. The performance of partial typing for HPV 16/18 combined with cytology (algorithm A) was analyzed against cytology without typing (algorithm B) for triaging HPV-positive women in primary screening.  Results: 12,5% of the women were HPV positive. Twenty-seven cases of CIN2+ were detected (10,8% of the positives). The sensitivity for detecting CIN2+ in HPV-positive women was greater for algorithm A than for B (A=77,7% vs B=44,4%, p=0,006). The specificity was higher for cytology without typing (A=68,7% vs B=77,2%, p=0,002) but with a lower detection rate for CIN2+. The positive predictive value (PPV) was similar (A=26,2% vs B=21,8%, p=0,30). The negative predictive value (NPV) was higher for genotyping with cytology (A=95,5% vs B=90,6%, p=0,014). The absolute risk for CIN2+ was 34,1% (95% CI 20,0-50,5) for genotypes 16/18 and 8,7% (95% CI 4,4-15,0) for other high-risk genotypes.  Conclusions: Partial typing of HPV followed by cytology presents a greater sensitivity for detecting CIN2+ lesions and is more efficient in ruling out disease compared to cytology as a triage method. HPV genotypes 16/18 should be referred for colposcopy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: O Vírus do Papiloma Humano (VPH), de alta prevalência, causa cêncer cervical em uma baixa porcentagem das infecções. A detecção de VPH deve ser complementada com um teste de triagem que identifique mulheres que estejam em maior risco de desenvolver cêncer.  Objetivo: Analisar as melhores estratégias de triagem para a detecção de lesões precoces e cêncer cervical.  Método: O estudo é retrospectivo e observacional. Foram realizados teste de Papanicolau, teste de VPH e tipificação em 1.984 mulheres no período de 2014 a 2019. Analisou-se o desempenho da tipificação parcial de VPH 16/18 combinada com citologia (algoritmo A) e da citologia sem tipificação (algoritmo B) para a triagem de mulheres VPH positivas no rastreio primário.  Resultados: 12,5% das mulheres foram VPH positivas. Foram detectados 27 casos de NIC2+ (10,8% das positivas). A sensibilidade para detectar NIC2+ em mulheres VPH positivas foi maior para o algoritmo A do que para o B (A=77,7% vs B=44,4%, p=0,006). A especificidade foi maior para a citologia sem tipificação (A=68,7% vs B=77,2%, p=0,002), mas com menor taxa de detecção de NIC2+. O VPP foi similar (A=26,2% vs B=21,8%, p=0,30). O VPN foi maior para a genotipificação com citologia (A=95,5% vs B=90,6%, p=0,014). O risco absoluto para NIC2+ foi de 34,1% (IC95% 20,0-50,5) para os genótipos 16/18 e 8,7% (IC95% 4,4-15,0) para outros genótipos de alto risco.  Conclusões: A tipificação parcial de VPH seguida de citologia apresenta maior sensibilidade para detectar lesões NIC2+ e é mais eficiente em descartar a doença em comparação com a citologia como método de triagem. Os genótipos de VPH 16/18 devem ser encaminhados para colposcopia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Neoplasias del cuello uterino]]></kwd>
<kwd lng="es"><![CDATA[Infecciones por papilomavirus]]></kwd>
<kwd lng="es"><![CDATA[Prueba de papanicolaou]]></kwd>
<kwd lng="es"><![CDATA[Cribado]]></kwd>
<kwd lng="es"><![CDATA[Test de detección de DNA de papillomavirus humano]]></kwd>
<kwd lng="en"><![CDATA[Uterine cervical neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Papillomavirus infections]]></kwd>
<kwd lng="en"><![CDATA[Papanicolaou test]]></kwd>
<kwd lng="en"><![CDATA[Screening]]></kwd>
<kwd lng="en"><![CDATA[Human papillomavirus DNA tests]]></kwd>
<kwd lng="pt"><![CDATA[Neoplasias do colo do útero]]></kwd>
<kwd lng="pt"><![CDATA[Infecções por papilomavírus]]></kwd>
<kwd lng="pt"><![CDATA[Teste de papanicolau]]></kwd>
<kwd lng="pt"><![CDATA[Triagem]]></kwd>
<kwd lng="pt"><![CDATA[Teste de detecção de DNA do papilomavírus humano]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saraiya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Unger]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Lyu]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[US assessment of VPH types in cancers: implications for current and 9-valent VPH vaccines]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2015</year>
<volume>107</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>djv086</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[zur Hausen]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2000</year>
<volume>92</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>690-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="">
<collab>International Agency for Research on Cancer</collab>
<article-title xml:lang=""><![CDATA[IARC monographs on the evaluation of carcinogenic risks to humans]]></article-title>
<source><![CDATA[Biological agents]]></source>
<year>2012</year>
<volume>100B</volume>
<publisher-loc><![CDATA[Lyon, France ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCredie]]></surname>
<given-names><![CDATA[MRE]]></given-names>
</name>
<name>
<surname><![CDATA[Sharples]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baranyai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Medley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2008</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>425-34</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berois]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[De Cremoux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mazal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sica]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cedeira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caserta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and distribution of high-risk human papillomavirus genotypes in invasive carcinoma of the uterine cervix in Uruguay]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2013</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>527-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castellsagué]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[de Sanjosé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2010</year>
<volume>202</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1789-99</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonde]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[M-T]]></given-names>
</name>
<name>
<surname><![CDATA[Gary]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review]]></article-title>
<source><![CDATA[J Low Genit Tract Dis]]></source>
<year>2020</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Comisión Honoraria de Lucha Contra el Cáncer. Cáncer de Cuello de Útero (C53) en Uruguay]]></article-title>
<source><![CDATA[Período 2015 &#8211; 2019]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Marzo ]]></publisher-loc>
<publisher-name><![CDATA[Registro Nacional de Cáncer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Bierman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Beardsley]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burk]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of cervicovaginal papillomavirus infection as measured by repeated DNA testing in adolescent and young women]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>338</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>423-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Mazloomzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Winter]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rollason]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Blomfield]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2005</year>
<volume>114</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>498-500</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palefsky]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy]]></article-title>
<source><![CDATA[Curr Opin Oncol]]></source>
<year>2003</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>382-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howley]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Lowy]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Papillomaviruses and their replication]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[En Howley]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Virology]]></source>
<year>2001</year>
<volume>2</volume>
<page-range>2197-229</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott/The Williams &amp; Wilkins Co]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Groves]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus genome integration in squamous carcinogenesis: what have next-generation sequencing studies taught us?]]></article-title>
<source><![CDATA[J Pathol]]></source>
<year>2018</year>
<volume>245</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-18</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papanicolaou]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new procedure for staining vaginal smears]]></article-title>
<source><![CDATA[Science]]></source>
<year>1942</year>
<volume>95</volume>
<numero>2469</numero>
<issue>2469</issue>
<page-range>438-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McCrory]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Bastian]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Hasselblad]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hickey]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2000</year>
<volume>132</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>810-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dürst]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gissmann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ikenberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[zur Hausen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions]]></article-title>
<source><![CDATA[Proc Natl Acad Sci]]></source>
<year>1983</year>
<volume>80</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3812-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lörincz]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening]]></article-title>
<source><![CDATA[J Obstet Gynaecol Res]]></source>
<year>1996</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>629-36</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Lorincz]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Wacholder]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (VPH) type 16 or 18 and the possible utility of type-specific VPH testing in clinical practice]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2005</year>
<volume>97</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1072-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ronco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dillner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Elfström]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Tunesi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Snijders]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arbyn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International VPH screening working group. Efficacy of VPH-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<numero>9916</numero>
<issue>9916</issue>
<page-range>524-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beracochea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caserta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tamizaje del cáncer de cuello uterino con test de HVP]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2019</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>267-80</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raine-Bennett]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Katki]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Gage]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Wentzensen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A large-scale evaluation of the cobas VPH test]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2015</year>
<volume>24</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1304-10</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbyn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Offering Self-Sampling Kits for VPH Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2015</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>769-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katki]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Fetterman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Poitras]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Lorey]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benchmarking CIN 3+ risk as the basis for incorporating VPH and Pap cotesting into cervical screening and management guidelines]]></article-title>
<source><![CDATA[J Low Genit Tract Dis]]></source>
<year>2013</year>
<volume>17</volume>
<numero>5 Suppl 1</numero>
<issue>5 Suppl 1</issue>
<page-range>S28-35</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wentzensen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arbyn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triage of VPH positive women in cervical cancer screening]]></article-title>
<source><![CDATA[J Clin Virol]]></source>
<year>2016</year>
<volume>76</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S49-55</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almonte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Picconi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2020</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e035796</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nayar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wilbur]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[The bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes]]></source>
<year>2015</year>
<edition>3rd ed.</edition>
<page-range>321</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer International Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoler]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aslam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ridder]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Huh]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Approaches to triage optimization in VPH primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2020</year>
<volume>146</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2599-607</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Stoler]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Behrens]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using VPH as the first-line screening test]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2015</year>
<volume>136</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>189-97</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanley]]></surname>
<given-names><![CDATA[SJB]]></given-names>
</name>
<name>
<surname><![CDATA[Fujita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aoyama-Kikawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kasamo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torigoe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuno]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of partial genotyping with VPH16/18 for triage of VPH positive, cytology negative women in the COMPACT study]]></article-title>
<source><![CDATA[J Gynecol Oncol]]></source>
<year>2021</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e86</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Engesæter]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Baadstrand Skare]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Bjørge]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tropé]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world data on cervical cancer risk stratification by cytology and VPH genotype to inform the management of VPH-positive women in routine cervical screening]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2020</year>
<volume>122</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1715-23</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pirog]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Lloveras]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Molijn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tous]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guimerá]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VPH prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases]]></article-title>
<source><![CDATA[Mod Pathol]]></source>
<year>2014</year>
<volume>27</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1559-67</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright Jr]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Stoler]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Behrens]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Apple]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Derion]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ATHENA human papillomavirus study: design, methods, and baseline results]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2012</year>
<volume>206</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46.e1-46.e11</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huh]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Ault]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Chelmow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Goulart]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2015</year>
<volume>136</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>178-82</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Kjaer]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Munk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ørnskov]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Waldstrøm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits and potential harms of human papillomavirus (VPH)-based cervical cancer screening: A real-world comparison of VPH testing versus cytology]]></article-title>
<source><![CDATA[Acta Obstet Gynecol Scand]]></source>
<year>2021</year>
<volume>100</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>394-402</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kinney]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Manos]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Hurley]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Ransley]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Where&#8217;s the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>1998</year>
<volume>91</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>973-6</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saslow]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Killackey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kulasingam]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Cain]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Cancer Society, American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer]]></article-title>
<source><![CDATA[Am J Clin Pathol]]></source>
<year>2012</year>
<volume>137</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>516-42</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Sanjose]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quint]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Alemany]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Geraets]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Klaustermeier]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Lloveras]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retrospective International Survey and VPH Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1048-56</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rijkaart]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Berkhof]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van Kemenade]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coupe]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Hesselink]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Rozendaal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of 14 triage strategies for VPH DNA-positive women in population-based cervical screening]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2012</year>
<volume>130</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>602-10</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjær]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Frederiksen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Munk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Iftner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2010</year>
<volume>102</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1478-88</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaljouw]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[EEL]]></given-names>
</name>
<name>
<surname><![CDATA[Aitken]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Harrijvan]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Naber]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[de Kok]]></surname>
<given-names><![CDATA[IMCM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reducing unnecessary referrals for colposcopy in hrVPH-positive women within the Dutch cervical cancer screening programme: A modelling study]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2021</year>
<volume>160</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>713-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
